Half Year 2026 Genscript Biotech Corp Earnings Call Transcript
Key Points
- Revenue exceeded $400 million with 27.3% year-over-year growth, and adjusted net profit surged over 200% to $62.5 million, demonstrating strong top-line and bottom-line performance.
- Life Science Group (LSG) delivered 28.8% revenue growth and doubled adjusted operating profit to $94 million, with operating margin approaching 30%, reflecting significant operational leverage.
- AI-driven drug discovery (AIDD) demand is a major growth engine, with orders projected to double in the second half and a structural shift toward recurring, high-volume validation services.
- ProBio achieved 34.2% revenue growth and a 54% increase in new orders, with adjusted EBITDA loss narrowing by over $10 million, signaling a clear path to profitability.
- The company raised its full-year guidance for LSG to 25-30% revenue growth and ProBio to 25-30%, underpinned by strong order momentum and a robust balance sheet with $830 million in cash.
- Bestzyme's adjusted operating loss widened to $1.3 million from $0.6 million in the prior year, reflecting deliberate investments that may pressure near-term profitability.
- The company faces potential competitive pressure from players like Twist Bioscience, though management argues its platform advantages are durable.
- AIDD-related orders carry higher margins but also require significant capacity expansion, with capital expenditures expected to reach $130 million in 2026, which could strain cash flow if demand softens.
- The company's growth is increasingly dependent on the nascent and rapidly evolving AIDD market, which carries execution risks and potential volatility in customer demand.
- Despite strong overall performance, the company's reliance on North America for 50% of revenue exposes it to regional economic and regulatory risks, including tariff impacts.
Good day, and thank you for standing by.
Welcome to JanScript Biotech 2026 Interim Results Conference Call.
At this time, all participants are in a listen-only mode.
After the speaker's presentation, there'll be a question-and-answer session.
To ask a question during the session, you need to press star 1 1 on your telephone.
You will then hear an automated message advising your hand is raised.
To withdraw your question, please press *11 again.
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, CFO of Genscript Biotech Group, Mr. Phil Zhou. Please go ahead.
Therefore, at Genescript, welcome to our 2026 Yingcheng Results Conference Call.
Joining me on the call today are Mr. Robin Meng, Chairman of the Board Mr. Sherry Shao, rotating CEO of Genescript Dr. Ray Chen. President of Chinsburg Life Science Group, Dr. Aisi Bai, General Manager of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
